Sun Pharmaceutical Industries (Sun Pharma) has withdrawn its appeal in the lawsuit filed by erstwhile Ranbaxy Laboratories in November 2014 in a U.S. District Court against U.S. Food and Drug Administration (FDA).
This lawsuit had challenged FDA’s revocation of Ranbaxy’s tentative approvals for its generic versions of Nexium and Valcyte in the U.S. In 2008 the USFDA had granted approval to Ranbaxy to sell the generic version of these two drugs after expiry of their patients but later on withdrew the approval forcing Ranbaxy to challenge the decision. Ranbaxy has been merged with Sun Pharma since early this year. Now that the lawsuit has been withdrawn, Sun Pharma said this move will not have any materially adverse financial impact on the company.
